Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bromfenac sodium in FEVR after laser
NCT05107921Phase 2Unknown
- Sponsor
- Seoul National University Hospital
- Start
- Nov 2021
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bromfenac sodium in Familial exudative vitreoretinopathy (FEVR), sponsored by Seoul National University Hospital. Primary endpoint: Macular edema response rate at 4 weeks. Status: unknown.
02
Drugs
bromfenac sodium
03
Conditions
Familial exudative vitreoretinopathy (FEVR)
Beyond the preview
Go deeper on NCT05107921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05107921.